1.
Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy. Biomol Biomed [Internet]. 2023 Dec. 1 [cited 2024 Jul. 3];:688–697. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/9838